prorso Guide Library Articles Features Enterprise
For teams
Sign inCreate account

Formulary decision on a new medicine at the margin of cost effectiveness

Open in the app

By · Published

An NHS integrated care board's medicines committee decides whether to list a new medicine, restrict it to a subgroup, defer pending a better price, or decline. The log states the displaced health expl...

The options

The question: Should the medicines committee add the new medicine to the formulary without restriction, add it restricted to a defined subgroup, decline pending a revised commercial offer, or decline to list it?

Option 1: List without restriction, for the full licensed population

For

  • Rationale. Unrestricted listing has the strongest evidence base of the options, because the submitted analysis is complete and clinically plausible for exactly this population.

Against

  • Risk. At a ratio above the threshold the system loses more health than the medicine provides. The patients who lose it are not identifiable and will never know, which is what makes this the easiest harm in the decision to discount.
  • Risk. Once 900 patients are established on the medicine the decision is effectively permanent, and a later price rise or evidence revision would be met from a position with no practical option to withdraw.
  • Research. Work by Claxton and colleagues on the estimation of the NICE cost-effectiveness threshold describes the threshold as an estimate of health forgone as other activity is displaced to accommodate the additional cost of a new technology. On that account, a ratio above the threshold means the system loses more health than the medicine delivers. The net health effect criterion below states that directly, at £25,000 per QALY, rather than leaving it implicit in a ratio.

Option 2: List restricted to the subgroup with more severe disease, where the modelled benefit is larger

For

  • Rationale. Restricting to the more severe subgroup directs the medicine to the patients in whom the modelled benefit is largest, which is the response the appraisal methods contemplate when a technology is cost effective for part of a licensed population and not for all of it.

Against

  • Risk. A subgroup defined after the trial, which was not powered for it, will usually produce a ratio that looks acceptable. The committee would be relying on the least robust number in the submission to justify the option that appears most reasonable.
  • Risk. Two previous restricted listings drifted beyond their criteria within two years with no audit in place to detect it. If prescribing drifts here, the organisation has adopted the unrestricted option without deciding to, and at the unrestricted option's net health effect.
  • Guidance. NICE methods have required probabilistic sensitivity analysis in submitted appraisals since 2004, and parameter values used in base case and sensitivity analyses are expected to be clinically plausible and consistent with the data. The submitted analysis meets this requirement for the whole licensed population but is sparse for the subgroup, which bears on the certainty recorded for the restricted option.

Option 3: Decline to list pending a revised commercial offer, with the ratio the offer would need to reach stated

For

  • Rationale. The obstacle to listing is the price rather than the evidence, and stating the ratio a revised offer would need to reach makes the decision reviewable and gives the manufacturer something specific to respond to.
  • Rationale. Deferral preserves every option. Listing later is possible; withdrawing later, once patients are established, is largely not.
  • Recommendation. That the committee decline to list pending a revised commercial offer, and state that the offer must bring the full-population ratio to no more than £25,000 per QALY, the point at which the net health effect is no longer negative at the threshold this log applies. On the submitted model that means reducing the net additional cost by about two-fifths, from about £3.1m to about £1.9m a year. At the submitted price the medicine displaces more health than it delivers, about 48 QALYs a year net, and the patients who lose that health are unidentifiable, which is a reason to weigh them carefully rather than a reason to discount them. The restricted option is not recommended despite its more favourable ratio: that ratio comes from a subgroup analysis the submission does not adequately support, its net health effect is about zero even on that analysis, and prescribing has previously drifted beyond stated restrictions undetected.

Against

  • Risk. Patients who would benefit are not treated while the position is held, and the wait is indefinite because the committee does not control whether an offer comes. That cost falls on identifiable patients, unlike the displaced health, which is why it will be argued more forcefully.

Option 4: Decline to list

For

  • Rationale. Declining is the clearest statement of the committee's position and does not hold out a prospect the committee cannot deliver.

Against

  • Risk. It forecloses a price negotiation that the deferral option keeps open, at no benefit: the two options have identical figures on every criterion, and what separates them is that the deferral states what would change the answer.
  • Risk. A decline recorded without stating what would change the answer is harder to defend to patients and clinicians than one that does, and invites the reading that the committee decided on cost alone.

Criteria and values

CriterionOption 1Option 2Option 3Option 4
Annual budget impact (lower is better)3,100,000 GBP1,050,000 GBP0 GBP0 GBP
Certainty of the evidence (higher is better)highlow——
Incremental cost per QALY (lower is better)41,00027,000——
Net health effect (higher is better)-48—00
Patients treated annually (higher is better)90031000
Assurance that prescribing stays within the terms (higher is better)highlowhighhigh
Ability to withdraw later (higher is better)lowmoderatehighhigh

What constrained the decision

Evidence

Related decisions

Open the decision log in the app

Spotted an error? Report a problem (ivan@ivanjureta.com). Corrections are listed on the page with their date.